- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
670
Companies which are more than 50% undervalued based on analyst price target.
670 companies
Coya Therapeutics
Market Cap: US$106.7m
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
COYA
US$6.27
7D
-4.4%
1Y
4.3%
Surrozen
Market Cap: US$106.7m
A biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
SRZN
US$12.20
7D
0.1%
1Y
32.1%
InflaRx
Market Cap: US$106.4m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$1.65
7D
3.1%
1Y
8.6%
Adagene
Market Cap: US$100.9m
A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
ADAG
US$2.20
7D
3.3%
1Y
-15.7%
JiangSu WuZhong Pharmaceutical Development
Market Cap: CN¥717.1m
JiangSu WuZhong Pharmaceutical Development Co., Ltd.
600200
CN¥1.02
7D
-6.4%
1Y
-87.7%
Pliant Therapeutics
Market Cap: US$100.1m
A biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
PLRX
US$1.86
7D
13.4%
1Y
-85.5%
Atossa Therapeutics
Market Cap: US$99.6m
Operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
ATOS
US$0.79
7D
3.3%
1Y
-40.8%
Pelthos Therapeutics
Market Cap: US$98.8m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$28.22
7D
19.3%
1Y
214.0%
Entera Bio
Market Cap: US$98.6m
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs.
ENTX
US$2.06
7D
6.7%
1Y
15.1%
AB Science
Market Cap: €83.4m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€1.20
7D
0%
1Y
19.8%
Connect Biopharma Holdings
Market Cap: US$97.5m
A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.
CNTB
US$1.75
7D
-15.0%
1Y
40.0%
BioPorto
Market Cap: DKK 612.0m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally.
BIOPOR
DKK 1.35
7D
4.8%
1Y
-29.3%
Anixa Biosciences
Market Cap: US$95.7m
A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
ANIX
US$2.97
7D
-0.7%
1Y
-7.5%
Champions Oncology
Market Cap: US$95.3m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.84
7D
0.6%
1Y
60.9%
Alto Neuroscience
Market Cap: US$95.0m
Operates as a clinical-stage biopharmaceutical company in the United States.
ANRO
US$3.67
7D
-0.3%
1Y
-72.1%
CervoMed
Market Cap: US$94.5m
A a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
CRVO
US$10.51
7D
9.3%
1Y
-26.8%
hVIVO
Market Cap: UK£68.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.
HVO
UK£0.10
7D
2.0%
1Y
-65.1%
Cardiol Therapeutics
Market Cap: CA$128.1m
A clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
CRDL
CA$1.54
7D
3.7%
1Y
-38.2%
ImmunoPrecise Antibodies
Market Cap: US$91.8m
MindWalk operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.
HYFT
US$1.94
7D
-18.1%
1Y
189.8%
Ovid Therapeutics
Market Cap: US$91.7m
A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
OVID
US$1.23
7D
-3.9%
1Y
20.6%
Kidswell Bio
Market Cap: JP¥13.4b
Develops pharmaceuticals for the treatment of rare and intractable diseases in Japan.
4584
JP¥281.00
7D
10.2%
1Y
126.6%
CEL-SCI
Market Cap: US$89.8m
A clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
CVM
US$10.49
7D
0.6%
1Y
-67.3%
Nanoform Finland Oyj
Market Cap: €75.4m
Engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States.
NANOFH
€0.88
7D
5.5%
1Y
-51.6%
Kalaris Therapeutics
Market Cap: US$87.2m
A clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
KLRS
US$4.62
7D
13.2%
1Y
n/a
Sutro Biopharma
Market Cap: US$86.5m
Operates as a oncology company.
STRO
US$1.06
7D
23.7%
1Y
-74.3%
Quince Therapeutics
Market Cap: US$86.2m
A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
QNCX
US$1.61
7D
0.6%
1Y
130.7%
Vaxart
Market Cap: US$86.0m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.
VXRT
US$0.38
7D
-3.5%
1Y
-57.5%
MPH Health Care
Market Cap: €72.8m
An investment company, engages in the healthcare business in Germany.
93M1
€17.55
7D
1.2%
1Y
-29.8%
Elutia
Market Cap: US$85.2m
A commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States.
ELUT
US$1.88
7D
-17.5%
1Y
-55.9%
OKYO Pharma
Market Cap: US$84.6m
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
OKYO
US$2.26
7D
-3.8%
1Y
121.6%
Fortress Biotech
Market Cap: US$84.5m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.71
7D
43.8%
1Y
109.6%
Trajan Group Holdings
Market Cap: AU$128.0m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.84
7D
-8.7%
1Y
-27.0%
Acumen Pharmaceuticals
Market Cap: US$83.6m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$1.44
7D
5.9%
1Y
-35.1%
Nautilus Biotechnology
Market Cap: US$82.3m
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
NAUT
US$0.66
7D
-2.8%
1Y
-74.1%
X4 Pharmaceuticals
Market Cap: US$81.8m
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
XFOR
US$3.50
7D
-6.8%
1Y
-82.1%
Satellos Bioscience
Market Cap: CA$112.8m
A biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.
MSCL
CA$0.66
7D
10.0%
1Y
32.0%